Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...

One of the new mechanics added in Marvel Rivals Season 1 was Recursive Destruction, and fans have been quite curious to know what it is all about. Marvel Rivals offers a variety of different maps that ...

Invoking DurableTaskClient.PurgeInstanceAsync with PurgeInstanceOptions.Recursive = true does not result in sub-orchestrations being purged. The documentation for this method states that ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. RXRX stock looks like a deep-value growth bet at just $5 ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug Administration ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) ...